Comparing the efficacy of efgartigimod and intravenous immunoglobulin on AQP4‐IgG‐positive neuromyelitis optica spectrum disorder during acute attacks
British Journal of Clinical Pharmacology · 2025-12 · 91 (12) · 3521-3528
DOI: 10.1002/bcp.70190 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 21.08.2025. Verfasst von Jia Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Neuromyelitis Optica, Aquaporin 4, Immunoglobulins, Intravenous. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Guangzhou Science and Technology Planning Project, Guangdong Basic and Applied Basic Research Foundation, Guangdong Medical Research Foundation.
Abstract (Originalsprache)
Aims
The aim of our study was to evaluate the efficacy of efgartigimod and intravenous immunoglobulin (IVIG) on AQP4‐IgG‐positive neuromyelitis optica spectrum disorder (NMOSD) patients during acute attacks.
Methods
A retrospective case–control study was designed to compare the clinical outcomes of 13 NMOSD patients treated with efgartigimod (at a dose of 20 mg/kg in the first and fifth day) and 20 NMOSD patients treated with IVIG (at 0.4 g/kg/day for 5 days). Follow‐up outcome information for patients is documented at 6 months postdischarge.
Results
Compared with IVIG, efgartigimod could improve NMOSD patients' symptoms during acute attacks, the mean Expanded Disability Status Scale score was significantly improved from 3.0 at admission to 2.5 at discharge ( P < .001). The serum IgG levels were obviously decreased in NMOSD patients treated with efgartigimod ( P < .001). Additionally, AQP4‐IgG titres in 5 NMOSD patients were found to turn negative after efgartigimod treatment.
Conclusion
The efficacy of efgartigimod is comparable to IVIG therapy in improving acute symptoms of AQP4‐IgG‐positive NMOSD. Efgartigimod could be an elegant alternative to IVIG therapy, and no serious adverse events were observed during infusion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
ORCID-Profile: Jia Liu
Förderung
- Guangzhou Science and Technology Planning Project
- Guangdong Basic and Applied Basic Research Foundation
- Guangdong Medical Research Foundation
Zitieren
APA
Liu, J., Li, M., Wu, H., Xu, X., Dai, K., Dong, R., Liu, J., Yang, L., Jiang, Y., & Peng, F. (2025). Comparing the efficacy of efgartigimod and intravenous immunoglobulin on AQP4‐IgG‐positive neuromyelitis optica spectrum disorder during acute attacks. British Journal of Clinical Pharmacology, 91(12), 3521-3528. https://doi.org/10.1002/bcp.70190
Vancouver
Liu J, Li M, Wu H, Xu X, Dai K, Dong R, et al. Comparing the efficacy of efgartigimod and intravenous immunoglobulin on AQP4‐IgG‐positive neuromyelitis optica spectrum disorder during acute attacks. British Journal of Clinical Pharmacology. 2025;91(12):3521-3528. doi:10.1002/bcp.70190
BibTeX
@article{Liu2025,
author = {Liu, Jia and Li, Min and Wu, Haotian and Xu, Xiaofeng and Dai, Kai and Dong, Ruiqi and Liu, Junyu and Yang, Lu and Jiang, Ying and Peng, Fuhua},
title = {Comparing the efficacy of efgartigimod and intravenous immunoglobulin on AQP4‐IgG‐positive neuromyelitis optica spectrum disorder during acute attacks},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
volume = {91},
number = {12},
pages = {3521--3528},
doi = {10.1002/bcp.70190}
}
EUVIMED